Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham CorpfiledCriticalSmithkline Beecham Corp
Publication of MX9300957ApublicationCriticalpatent/MX9300957A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere al tratamiento y prevención de condiciones en las que se indica la inhibición de la proteína Cinasa C, (PCC). En particular, se refiere al tratamiento de trastornos cardiovasculares y renales, inflamación trastornos del sistema nervioso central, inmonosupresión, y choque séptico, y al uso de ciertas 4,5,6,7-tetrahidropirrolo-(2,3-C)-azepin-8-onas en la fabricación de medicamentos para el tratamiento de tales condiciones.The present invention relates to the treatment and prevention of conditions in which the inhibition of protein Kinase C, (PCC) is indicated. In particular, it refers to the treatment of cardiovascular and kidney disorders, inflammation of the central nervous system disorders, immunosuppression, and septic shock, and the use of certain 4,5,6,7-tetrahydropyrrolo- (2,3-C) -azepin -8-ones in the manufacture of drugs for the treatment of such conditions.
MX9300957A1992-02-241993-02-22
USE OF 4,5,6,7-TETRAHIDROPIRROLO- (2,3-C) -AZEPIN-8-ONAS IN THE PREPARATION OF MEDICINES TO INHIBIT PROTEIN CINASA C.
MX9300957A
(en)
Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for prophylaxis and treatment of sequelae of reduced circulation in the brain and neurodegenerative disorders
DERIVATIVES OF 3-OXO-PIRIDO (1,2-A-) BENCIMIDAZOL-4-CARBOXYL AND 4-OXO-AZEPINO (1,2-A) BENCIMIDAZOL-5-CARBOXYL USEFUL IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM.